Wilmington Savings Fund Society’s Viking Therapeutics VKTX Stock Holding History

Wilmington Savings Fund Society’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3K	Buy	77 +7	+10%	+$226	﹤0.01%	1317
2026 Q1	$2.28K	Hold	70	–	–	﹤0.01%	1339
2025 Q4	$2.46K	Buy	+70	New	+$2.48K	﹤0.01%	1303
2025 Q3	–	Sell	-7,000	Closed	-$186K	–	2045
2025 Q2	$186K	Buy	7,000 +2,500	+56%	+$65.8K	﹤0.01%	828
2025 Q1	$109K	Hold	4,500	–	–	﹤0.01%	978
2024 Q4	$181K	Buy	+4,500	New	+$257K	﹤0.01%	865

Other funds holding VKTX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Wilmington Savings Fund Society's VKTX Position: Q2 2026 in Review

Wilmington Savings Fund Society increased its Viking Therapeutics (VKTX) stake by 10% in Q2 2026, buying an estimated $226 and bringing the position to 77 shares worth $3K. The position accounts for ﹤0.01% of the portfolio, ranked #1317.

Wilmington Savings Fund Society first reported a position in VKTX in Q4 2024 and has held it in 6 quarters since. The position peaked at $186K in Q2 2025. 432 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

Wilmington Savings Fund Society held 77 shares of Viking Therapeutics worth $3K as of Q2 2026.
Wilmington Savings Fund Society bought 7 Viking Therapeutics shares in Q2 2026, an estimated $226.
Viking Therapeutics made up ﹤0.01% of Wilmington Savings Fund Society's portfolio in Q2 2026, its #1317 holding.
Wilmington Savings Fund Society first reported a position in Viking Therapeutics in Q4 2024 and has held it in 6 quarters since.
Wilmington Savings Fund Society's Viking Therapeutics position peaked at $186K in Q2 2025.
432 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Wilmington Savings Fund Society's 13F filing for Q2 2026, filed 28 Jul 2026.